We all know it's important to choose "measures that matter" when selecting and developing digital measures for evidence generation in clinical trials, but how do we put these good intentions into action? How do we lay solid, patient-centric foundations, whether that means designing a protocol, building an integrated evidence plan, or qualifying a novel evidence tool?
Read More
In September 2022, a broad range of stakeholders representing regulators, Pharma and Biotech firms, technology service providers, innovators, and patients gathered in Zürich. This meeting, the second in a series hosted by the Swiss Federal Institute of Technology and the Foundation for the National Institutes of Health Biomarkers Consortium, sought to explore the role patient centricity must play in the development and validation of digital tools for gathering evidence. Director of Science Ieuan Clay, a member of the Biomarkers Consortium, represented VivoSense in the discussion examining four case studies of interest:
Read More
